VIVUS — Technical Presentation (May 2010)
21 slides from VIVUS's technical presentation, May 4, 2010
Slide 1: Once-Daily, Low-Dose PHEN/TPM CR Improves Blood Pressure and Results in Weight Loss
Suzanne Oparil, MD Professor of Medicine, Physiology and Biophysics Director, Vascular Biology and Hypertension Program Division of Cardiovascular Disease Department of Medicine University of Alabama at Birmingham Birmingham, Alabama Once-Daily, Low-Dose, Controlled-Release Phentermine/Topiramate (P
Slide 2: Disclosure of Relationships
American Society of Hypertension, Inc. (ASH) Disclosure of Relationships Over the past 12 months Grant/Research Support: Daiichi Sankyo Inc., Gilead, and Takeda Consultant: Boehringer Ingelheim, Daiichi Sankyo Inc., Eli Lilly, Forest Laboratories, NicOx, Novartis, Schering-Plough, The Salt Institute
Slide 3: Learning Objectives
American Society of Hypertension, Inc. (ASH) Learning Objectives Upon completion of this activity, participants should be better able to Explain the current unmet need for safe and effective weight loss and its implications for obesity-related comorbidities Describe the unique formulation of PHEN/TP
Slide 4: Overview
Overview The prevalence of overweight and obese adults (BMI >25 kg/m2) is 68% (NHANES 2007-2008) and is on the rise1 Obesity is associated with excess mortality due to comorbidities (eg, cardiovascular disease, diabetes, hypertension)2,3 Standard treatments for obesity (diet and exercise) often achi
Slide 5: Phentermine and Topiramate
Phentermine and Topiramate Phentermine (PHEN)1-3 FDA approved (1959) as a short-term adjunct to diet and exercise Stimulates neurons to release or maintain high levels of catecholamines that may cause Appetite suppression by increasing blood leptin levels A decrease in neuropeptide Y production, whi
Slide 6: Integrated Efficacy Analysis of PHEN/TPM CR
Integrated Efficacy Analysis of PHEN/TPM CR Objectives To evaluate weight loss over a 28-week period in overweight and obese subjects (6-month cohort) To evaluate change in SBP and DBP over a 28-week period (6-month cohort) To confirm maintenance of weight loss and change in blood pressure through 5
Slide 7: Study Designs
Study Designs Pooled analysis of Phase 3, randomized, double-blind, placebo-controlled, multicenter clinical studies OB-301 (EQUATE): compared full-dose (15/92) and mid-dose (7.5/46) PHEN/TPM CR with placebo and the respective single-agent PHEN and TPM components after 28 weeks of treatment in obese
Slide 8: Baseline Demographics
Baseline Demographics Placebo (n=1580) PHEN/TPM CRL 3.75/23 (n=234) 7.5/46 (n=591) 15/92 (n=1582) Age, years Mean (SD) 48.3(11.5) 43.0(11.1) 50.0(10.8) 47.8(12.0) Gender, n (%) Female 1182 (74.8) 194 (82.9) 422 (71.4) 1175 (74.3) Male 398 (25.2) 40(17.1) 169 (28.6) 407 (25.7) Race, n (%) White 1330
Slide 9: Primary Outcome at Week 28
Primary Outcome at Week 28 LS mean percent weight loss of the ITT-LOCF population was significantly greater for all doses of PHEN/TPM CR at 28 weeks Percent Weight Loss From Baseline to Week 28 for EQUATE, EQUIP, and CONQUER (ITT-LOCF)
Slide 10: Primary Outcome at Week 56
Primary Outcome at Week 56 Percent Weight Loss From Baseline to Week 56 for CONQUER and EQUIP (ITT-LOCF) LS mean percent weight loss for the 1-year ITT-LOCF population was maintained across all doses of PHEN/TPM CR at 56 weeks
Slide 11: Change in SBP and DBP at Week 28 (ITT-LOCF)
Change in SBP and DBP at Week 28 (ITT-LOCF) LS Mean Change in SBP and DBP From Baseline to Week 28 Parameter/Treatment n LS Mean (SE) Systolic Blood Pressure, mm Hg Placebo 1579 -3.06(0.370) PHEN/TPM CR 3.75/23* 234 -5.13(0.850) PHEN/TPM CR 7.5/46* 590 -6.77(0.534) PHEN/TPM CR 15/92* 1581 -6.51 (0.3
Slide 12: Change in SBP Compared With Placebo (ITT-LOCF)
Change in SBP Compared With Placebo (ITT-LOCF) Dose LS Mean Difference (95%CI) PHEN/TPM CR 15/92 EQUATE Week 28 LOCF (n=103) EQUIP Week 56 LOCF (n=498) CONQUER Week 56 LOCF (n=980) -3.4 (-6.2 to -0.5) -3.8 (-5.2 to -2.5) -3.2 (-4.3 to-2.1) PHEN/TPM CR 7.5/46 EQUATE Week 28 LOCF (n=102) -5.2 (-8.1 to
Slide 13: Change in DBP Compared With Placebo (ITT-LOCF)
Change in DBP Compared With Placebo (ITT-LOCF) Dose LS Mean Difference (95%CI) -1.3 (-3.3 to 0.8) -1.9 (-2.8 to-0.9) -1.1 (-1.9 to-0.4) PHEN/TPM CR 15/92 EQUATE Week 28 LOCF (n=103) EQUIP Week 56 LOCF (n=498) CONQUER Week 56 LOCF (n=980) PHEN/TPM CR 7.5/46 EQUATE Week 28 LOCF (n=102) -1.4 (-3.5 to 0
Slide 14: Hypertension Subgroup: Weight Loss
Hypertension Subgroup: Weight Loss Percent Weight Loss From Baseline to Week 56 for Subjects With Hypertension in CONQUER (ITT-LOCF) LS mean percent weight loss achieved by the hypertension subgroup was similar to that of entire integrated population at 56 weeks
Slide 15: Hypertension Subgroup: Change in SBP and DBP
Hypertension Subgroup: Change in SBP and DBP Change in SBP and DBP From Baseline to Week 56 for Subjects With Hypertension in CONQUER (ITT-LOCF) Hypertensive patients treated with PHEN/TPM CR experienced significant LS mean changes in SBP and DBP vs placebo at 56 weeks
Slide 16: Hypertension Subgroup: Change in Concomitant Antihypertensive Medications
Net Percent of Patients With an Increase/Decrease in Number of Antihypertensive Medications From Baseline to Week 56 for Subjects With Hypertension in CONQUER (ITT-LOCF) The placebo group had an increase in the number of concomitant antihypertensive medications while the PHEN/TPM CR groups had a dec
Slide 17: Most Frequently Reported Adverse Events From EQUATE, EQUIP, and CONQUER
Most Frequently Reported Adverse Events From EQUATE, EQUIP, and CONQUER TEAE in >5% of Subjects in Any Treatment Group, % 6-Month Cohort (N=4072) 1-Year Cohort (N=3749) Placebo (n=1615) 3.75/23 (n=240) 7.5/46 (n=604) 15/92 (n=1613) Placebo (n=1506) 3.75/23 (n=240) 7.5/46 (n=498) 15/92 (n=1505) Alter
Slide 18: Integrated Safety Analysis of Phase 3 Trials
Integrated Safety Analysis of Phase 3 Trials Most AEs were mild or moderate in severity The distributions of AEs by maximum severity were similar for the placebo and PHEN/TPM CR treatment groups Discontinuations due to AEs in the 1-year population: 8.5% (placebo), 11.7% (3.75/23), 11.6% (7.5/46), 17
Slide 19: Summary
Summary This integrated analyses of 3 pivotal Phase 3 trials (EQUATE, EQUIP, and CONQUER) demonstrates the safety and efficacy of treatment with PHEN/TPM CR across a broad subject population PHEN/TPM CR treatment achieved comparable weight loss in subjects with hypertension Among subjects with hyper
Slide 20: Acknowledgments
Acknowledgments
Slide 21: Disclosure of Relationships
American Society of Hypertension, Inc. (ASH) Disclosure of Relationships Over the past 12 months Grant/Research Support: Daiichi Sankyo Inc., Gilead, and Takeda Consultant: Boehringer Ingelheim, Daiichi Sankyo Inc., Eli Lilly, Forest Laboratories, NicOx, Novartis, Schering-Plough, The Salt Institute